Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Indivior Pharmaceuticals Inc (INDV)

286 + Investors. Track Smart Money conviction in INDV. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +31
Streak
11Q ▲
Buyers last Q
56%

Smart Money Signals — INDV

Based on 287 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 11 quarters in a row

last 6Q
For 11 consecutive quarters, more hedge funds added INDV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
287 hedge funds hold INDV right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +154% more funds vs a year ago

fund count last 6Q
+174 new funds entered over the past year (+154% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 56% buying

179 buying140 selling
Last quarter: 179 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 39 → 91 → 90 → 83. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 59% entered in last year

■ 15% conviction (2yr+) ■ 26% medium ■ 59% new
Only 42 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares -2%, value -19%

Value
-19%
Shares
-2%
Last quarter: funds added -2% more shares while total portfolio value only changed -19%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

24 → 39 → 91 → 90 → 83 new funds/Q
New funds entering each quarter: 39 → 91 → 90 → 83. A growing number of institutions are discovering INDV each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🌱

Early stage — 66% of holders entered in last year

■ 19% veterans ■ 15% 1-2yr ■ 66% new
Of 293 current holders: 193 (66%) entered in the past year, only 56 (19%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 35% AUM from major funds

35% from top-100 AUM funds
50 of 285 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
6.3
out of 10
Moderate Exit Risk
Exit risk score 6.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — INDV

In 2026 Q1, 179 hedge funds were net buyers of INDV (83 opened a new position, 96 added to an existing one), while 140 reduced or exited (88 trimmed, 52 sold completely) — a 56% buyer ratio, indicating a slight buying edge. This marks 11 consecutive quarters of net institutional buying — a persistent conviction signal. 35% of total institutional value in INDV is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +31 funds (more new holders than closures). Total institutional holders: 287.

Hedge Fund Ownership: INDV

How many hedge funds hold INDV — quarterly history vs. share price
Quarterly hedge fund ownership of INDV vs. share price

Market Analysis: INDV

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: INDV

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Indivior Pharmaceuticals Inc (INDV) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much INDV has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
INDV
+24.4%
XLV
+2.8%

INDV outperformed XLV by +21.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
INDV
+3.2%
XLV
+3.9%

Since the filing became public, INDV outperformed XLV by -0.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

26 top-rated funds 4 high-conviction
Consensus
6.2
/ 10
breadth
×
Elite
4.2
/ 10
conviction
Hedge Fund Positioning: INDV
286 + Investors

Track Smart Money conviction in INDV. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 286 256 11.72%
13F Shares 121M 124M -2.37%
Total Value $3.57B $4.43B -19.36%
New Positions 82 90 -8
Increased Positions 93 81 +12
Closed Positions 52 27 +25
Reduced Positions 86 67 +19
Total Calls 4 8 -50.0%
Total Puts 3 3 -
PUT/CALL Ratio 0.75 0.38 Neutral

Statistics: INDV

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

286 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in INDV. Verified SEC 13F-HR filings.

QUARTER:
Top 25 INDV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Mangrove Partners IM, LLC 6.76% 2,742,434 $83.6M
2 Newtyn Management, LLC 6.51% 2,000,000 $61.0M
3 Madison Avenue Partners, LP 5.72% 4,315,162 $131.5M
4 Alta Fundamental Advisers LLC 4.70% 409,529 $12.5M
5 Bardin Hill Management Partners LP 2.63% 87,611 $2.1M
6 Sandro Wealth Management LLC 2.35% 96,164 $2.9M
7 Melqart Asset Management (UK) Ltd 2.06% 684,320 $20.9M
8 Two Seas Capital LP 2.02% 4,746,510 $144.7M
9 PFM Health Sciences, LP 1.60% 574,666 $17.5M
10 Soleus Capital Management, L.P. 1.57% 1,274,000 $38.8M
11 Riposte Capital LLC 1.55% 200,000 $6.1M
12 Tejara Capital Ltd 1.13% 112,400 $3.4M
13 Deerfield Management Company, L.P. 1.11% 3,097,790 $94.4M
14 Clark Estates Inc/Ny 0.68% 92,300 $2.8M
15 Divisadero Street Capital Management, LP 0.66% 521,083 $15.9M
16 Oberweis Asset Management Inc/ 0.59% 653,413 $19.9M
17 Fuller & Thaler Asset Management, INC. 0.46% 4,529,583 $138.1M
18 Gendell Jeffrey L 0.46% 1,096,343 $33.4M
19 Florida Financial Advisors, LLC 0.43% 58,687 $1.8M
20 Navellier & Associates Inc 0.43% 134,108 $4.1M
21 Driehaus Capital Management LLC 0.42% 1,880,039 $57.3M
22 Diadema Partners LP 0.37% 71,376 $2.2M
23 Integrated Quantitative Investments LLC 0.37% 66,843 $2.0M
24 Rock Springs Capital Management LP 0.36% 200,000 $6.1M
25 Hennion & Walsh Asset Management, Inc. 0.34% 330,691 $10.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Indivior Pharmaceuticals Inc (INDV)

What does the Smart Money Trend signal show for INDV?

Buying streak — 11 quarters in a row: For 11 consecutive quarters, more hedge funds added INDV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for INDV?

Slight buying edge — 56% buying: Last quarter: 179 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for INDV holders?

Strong quality — 35% AUM from major funds: 50 of 285 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held INDV?

Mostly new holders — 59% entered in last year: Only 42 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Indivior Pharmaceuticals Inc (INDV) following the 2026 Q1 hedge fund 13F filings?

As of today, INDV has moved +3.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -0.7%. Since the quarter end (March 31, 2026), INDV has gained +24.4% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →